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Fungal infections in humans have increased alarmingly in recent years, particularly in immunocompromised individuals. Among
the infections systemic candidiasis, aspergillosis, cryptococcosis, paracoccidioidomycosis, and histoplasmosis mortality are more
prevalent and more severe in humans. The current high incidence of dermatophytosis is in humans, especially as the main
etiologic agents Trichophyton rubrum and Trichophyton mentagrophytes. Molecules pristimerin and maytenin obtained from the
plant Maytenus ilicifolia (Celastraceae) are known to show various pharmacological activities. This study aimed to evaluate the
spectrum of antifungal activity of maytenin and pristimerin and their cytotoxicity in human keratinocytes (NOK cells of the oral
mucosa).ItwasconcludedthatthebestspectrumofantifungalactivityhasbeenshowntomayteninwithMICvaryingfrom0.12to
125mg/L, although it is also active with pristimerin MIC ranging between 0.12 and 250mg/L. Regarding the toxicity, both showed
to have high IC50. The SI showed high pristimerin against some species of fungi, but SI maytenin was above 1.0 for all fungi tested,
showing a selective action of fungi. However, when comparing the two substances, maytenin also showed better results. The two
molecules can be a possible prototype with a broad spectrum of action for the development of new antifungal agents.
1.Introduction
Fungal infections are mainly caused by opportunistic fungi
and are usually associated with immunosuppression [1].
Over the past two decades, invasive fungal infections have
emerged as a major threat to immunocompromised patients,
since species of Aspergillus, Candida, Cryptococcus, and
Histoplasma emerging pathogens such as Fusarium and
Trichophyton can cause infection when defenses of host are
broken [1]. Paracoccidioidomycosis is a fungal infection that
isveryimportant,whichaﬀectsalargepercentageoftherural
population of Latin America [2].
There is now a great interest in the discovery of new
molecules of natural origin for the treatment of various
diseases [3] .N a t u r a lp r o d u c t sh a v ep r o v i d e daw i d ev a r i e t y
of drugs and have become an alternative to large demand
for new antifungal drugs [4]. In Brazil, the use of medicinal
plants in traditional medicine has increased considerably in
recent years. The wide distribution of natural resources in
Brazilian ecosystems and natural diversity of chemical com-
ponents and provides the country with potential bioactive
materials [5].
Maytenus ilicifolia (Celastraceae), popularly known as
“espinheira santa,” has been used in traditional medicine
since the mid-1920s [6]. The secondary metabolites,
maytenin and pristimerin (Figure 1), are classiﬁed as
quinonemethide triterpenoids and mainly isolated from
the bark of the roots of mature M. ilicifolia plants [7].
Several studies have shown that maytenin exhibits strong
antimicrobial activity against Gram-positive and Gram-
negative organisms, but there are no studies detailing the
eﬀects of these substances on fungi [8].2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Structures of the isolated quinonemethide triterpenes from M. ilicifolia, pristimerin (1) and maytenin (2).
The need to discover new antifungal molecules and
natural products is of great importance for the development
ofnewtherapeutictools.Thispaperproposesthestudyofthe
potential antifungal potential of maytenin and pristimerin
against fungi, an agent of important mycoses. The potential
broad spectrum of these molecules was evaluated, and the
cytotoxicity of these substances in cell lines was evaluated,
s u g g e s t i n gp o s s i b l ep r o t o t y p e so fab r o a ds p e c t r u mo f
components for the treatment of mycoses.
2. Methods
2.1. Microorganisms. ATCC strains and clinical isolates
belong to the mycology collection of the Laboratory of
Clinical Mycology, Department of Clinical Analysis, Faculty
of Pharmaceutical Sciences, UNESP, Araraquara, were used
in the current study. The strains used were: Candida albicans
ATCC 90028, Candida krusei ATCC 6258, Candida parap-
silosis ATCC 22019, Candida glabrata ATCC 90030, Candida
tropicalis ATCC 750, Cryptococcus neoformans var. grubii
ATCC 90012, Histoplasma capsulatum (G217B), Aspergillus
niger ATCC 16404, Aspergillus fumigatus ATCC 7100, Tri-
chophyton interdigitalis ATCC 40131. Clinical isolates from
Paracoccidioides brasiliensis (18), Trichophyton rubrum and
Trichophyton mentagrophytes (102), Cryptococcus neoformans
var. grubii resistant to ﬂuconazole (R30), two clinical isolates
from Cryptococcus neoformans var. grubii susceptible to ﬂu-
conazole (S26 and S27), and Cryptococcus gattii (118) isolate
from animals, resistant to ﬂuconazole, and Histoplasma
capsulatum (M238P) (lung bat) were also used.
2.2. Minimum Inhibitory Concentration (MIC). All microor-
ganisms were tested for susceptibility to speciﬁc commercial
drugs for the treatment of each gender. The test for yeast
was carried out in accordance with the microdilution
method described according to the M27-S3 of the CLSI
(Clinical and Laboratory Standards Institute) (2008), with
modiﬁcations. The ﬁlamentous fungi susceptibility testing
was performed according to the M38-A2 of the CLSI (2008)
[9]withmodiﬁcationstodeterminetheminimuminhibitory
concentration (MIC).
Two pure substances extracted from Maytenus ilicifo-
lia, maytenin and pristimerin, were prepared as described
byScorzoni et al. 2007 [10]. The antifungal drugs were
diluted according to CLSI M27-S3 [9]. Inoculums were
prepared in RPMI-1640 (Sigma-Aldrich, St. Louis, MO,
USA) with L-glutamine, without sodium bicarbonate, sup-
plemented with 2% glucose, and buﬀered to a pH of 7.0
using 0.165M MOPS, (Sigma-Aldrich, St. Louis, MO, USA).
The yeast suspension was adjusted to a ﬁnal concentration
of 1.0 × 104 CFU/mL in RPMI-1640 and for ﬁlamentous
fungi, a suspension of microconidia was adjusted to 2.5 to
5.0 × 103. In the 96-well plates, substances were added in
serial dilutions, starting from a concentration of 250mg/L
to 0.48mg/L. The plates were incubated in a shaker at
37◦C/150rpm to a speciﬁc time determined for each
microorganism. The reading of MIC was performed by
spectrophotometry at 490nm and conﬁrmed using Alamar
Blue (Sigma-Aldrich, St. Louis, MO, USA).
2.3. Minimum Fungicide Concentration (MFC). A qualitative
analysis of fungal viability was performed, by transferring
a portion of the wells to a plate with Sabouraud (Sigma-
Aldrich, St. Louis, MO, USA) medium and incubated at
37◦C during the time determined for each fungal agent. The
MFC was determined as the lowest concentration of the
extract that did not allow the growth of any fungal colony
on the solid medium after the incubation period [11]. A
visualreading wasperformedtoconﬁrmthedeathorgrowth
inhibition provided by the antifungal substances, maytenin
and pristimerin.
2.4. Cell Cytotoxicity Assay. The cytotoxicity of maytenin
and pristimerin was assessed by MTT for cell lines NOKEvidence-Based Complementary and Alternative Medicine 3
Table 1: MIC values and quantitative analysis of fungal cellular viability of pure substances maytenin and pristimerin front of the yeasts and
ﬁlamentous pathogenic strains causing the most mycoses and evaluation of cytotoxic activity in NOK cells and selectivity index from the
ratio of the IC50 and MFC.
Maytenin
MIC/MFC
Pristimerin
MIC/MFC
Amphotericin
Br e f e r e n c e
values MIC
Itraconazole
reference
values MIC
Maytenin
IC50
(mg/L)/SI
Pristimerin
IC50
(mg/L)/SI
Candida albicans ATCC
90028 62.50/62.50 250.00/250.00 0.50–2.00 — 265.7/4.25 ∗
Candida krusei ATCC 6258 15.62/62.50 7.81/62.50 0.25–2.00 0.12–0.50 78.33/1.25 24.25/0.38
Candida parapsilosis ATCC
22019 15.62/31.25 125.00/125.00 0.25–1.00 0.06–0.25 78.33/2.50 ∗
Candida tropicalis ATCC 750 15.62/31.25 31.25/62.52 0.50–2.00 — 78.33/2.50 203.98/3.26
Candida glabrata ATCC
90030 31.25/31.25 125.00/125.00 0.25–1.00 — 203.98/6.52 ∗
Cryptococcus neoformans
ATCC 90012 0.48/0.48 0.97/0.97 0.50 0.125 2.53/5.29 3.92/4.04
Cryptococcus neoformans
R30 3.90/3.90 7.81/7.81 1.00 >32.00 22.18/5.68 24.25/3.10
Cryptococcus neoformans
isolated 26 0.48/0.48 1.95/1.95 0.50 0.125 2.53/5.29 6.41/3.28
Cryptococcus neoformans
isolated 27 0.48/0.48 3.90/3.90 0.50 0.125 2.53/5.29 20.10/5.15
Cryptococcus gattii 118 1.95/1.95 3.90/3.90 1.00 >32.00 9.84/5.05 20.10/5.15
Paracoccidioides brasiliensis
Pb18 <0.12/- <0.12/- 0.015–0.25 <0.0039 ∗∗ ∗∗
Histoplasma capsulatum
ATCC 0G217B 0.97/0.97 0.48/0.48 0.06–0.25 0.25–2.00 3.70/3.81 6.43/13.40
Histoplasma capsulatum
isolated M238P 0.48/0.48 0.48/0.48 0.06–0.25 0.25–2.00 2.53/5.29 6.43/13.40
Aspergillus fumigatus ATCC
7100 125/- >250/- 0.12–2.0 0.12- > 16.00 ∗∗
Aspergillus niger ATCC
16404 0.97/0.97 250/250 0.12–0.5 0.12–1.00 3.70/3.81 ∗
Trichophyton rubrum clinical
isolated 1.95/1.95 250/250 — 0.03–4.00 9.84/5.05 ∗
Trichophyton mentagrophytes
ATCC 40131 3.9/3.9 62.5/250 — 0.03–0.25 22.18/5.68 150.24/0.6
Trichophyton mentagrophytes
clinical isolated 102 3.9/3.9 125/250 — 0.03–0.25 22.18/5.68 ∗
MIC: minimum inhibitory concentration; MFC: minimum fungicide concentration.
 IC50/ I Sv a l u e si nN O Kc e l l s .
∗ IC50/IS not apply because the MIC and MFC values are above 62.5mg/L.
∗∗ IC50/IS not apply because the MIC and MFC values are below 0.12mg/L.
IC50: 50% inhibitory concentration. SI: selectivity index obtained from the relationship between the IC50 (NOK) by MFC for each fungi.
(keratinocyte oral mucosa), obtained from the American
TypeCultureCollection(Manassas,VA,USA).Thecellswere
grown in own culture medium NOK (Keratinocytes—SFM,
GIBCO),andmaintainedat36.5◦C.Aconcentrationranging
f r o m2 . 5t o5 .0 × 104 cells/mL was used for the formation
of monolayer cells. The concentrations of pure substances
were kept in contact with the cells for 24 hours. After the
incubation period, the cells treated with the MTT reagent
has an additional 5mg/mL added, (Sigma-Aldrich, St. Louis,
MO, USA) and the cells were incubated again for another
4h. After the formation of formazan crystals, 100µLo f
isopropanol was added to solubilize the precipitate and allow
thereadingoftheresultbychangingthecolorofthemedium
[12]. The absorbance of formazan was quantiﬁed using an
ELISA reader (enzyme-linked immunosorbent assay) set at
560nm. As a positive control test, hydrogen peroxide was
used.
3. Results
3.1. Minimum Inhibitory Concentration (MIC). Table 1
present the results of the antifungal activity of maytenin
and pristimerin, isolated from Maytenus ilicifolia. Maytenin
activity was classiﬁed as potent for both yeasts and for
ﬁlamentous fungi, when compared to positive controls
itraconazole and amphotericin B; since the MIC ranged4 Evidence-Based Complementary and Alternative Medicine
between 0.12 and 62.5mg/L. Pristimerin previously showed
a signiﬁcant variation in the action potential. For yeasts, the
pristimerin showed potent activity, with the exception of C.
glabrataATCC90030whichshowedmoderateactivityandC.
albicans ATCC 90028, which presented low antifungal activ-
ity. For the ﬁlamentous fungi, pristimerin showed moderate
activity, with the exception of Trichophyton mentagrophytes
ATCC 40131, which showed a MIC of 62.5mg/L and was
classiﬁed as having potent activity.
3.2. Minimum Fungicide Concentration (MFC). Minimum
fungicide concentration was performed to conﬁrm cell death
in MIC through observation of no colony growth in a rich
medium. The maytenin showed fungicide activity for most
yeasts. No growth of C. albicans colonies was observed, and
thedeathofyeastoccurredinahigherdilutionconcentration
(Table 1). For the ﬁlamentous fungi, MFC was conﬁrmed by
testing cell viability, which occurs in MIC fungal cell death
(Table 1).
Pristimerin presented a greater diﬀerence between the
MIC and MFC. Moreover, the diﬀerence between the MIC
and the value of qualitative analysis of fungal viability was
greater than the diﬀerence presented by maytenin (Table 1).
For the fungus Paracoccidioides brasiliensis and the ﬁla-
mentousfungiAspergillusnigerandfumigatus,thequalitative
test of fungal viability was ﬂawed, since the growth of
colonies cannot be observed on a solid medium.
3.3. Cell Cytotoxicity Assay. The cytotoxicity assay for the
NOK cell line showed more than 80% of cell viability in MIC
maytenin concentrations. The substance pristimerin showed
cell viability above 80% in normal cells (Table 1).
4. Discussion
Plants have been used in medicine for a long period of
time, since they are easy to obtain and apply various diseases
[4, 13]. Regarding the search for new antifungal agents,
the ideal must have a broad spectrum of fungicidal activity
without causing toxicity to the host [14]. The treatment of
fungal infections is not always eﬀective because of resistance
to drugs in addition to presenting high toxicity for human
cells. For this reason, there is a continuing search for new
drugs which are more potent antifungal, but safer, than
existing drugs [15].
The present study showed that pristimerin and maytenin
had potente action on the fungi studied (Table 1), but
maytenin showed the best results. The exception was
HistoplasmacapsulatumisolatedM238PandParacoccidioides
brasiliensis which showed MIC equal for both substances.
Alan´ ıs-Garza et al., 2007 [16] studied the anti-
Histoplasma activity of extracts obtained from various plants
and showed MICs between 16 and 125mg/L. This study
s h o w e da nM I Cf o rA T C Cs t r a i n so fH. capsulatum 0.97 and
less than 0.48mg/L pristimerin and maytenin respectively,
while for clinical isolate, the MIC for the two substances was
less than a 0.48mg/L. Compared with few literary data of
natural products active against this fungal, pristimerin and
maytenin can be considered prototypes that are excellent
anti-Histoplasma.
Few studies have searched for new drugs from natural
products for P. brasiliensis [17, 18]. There are reports of
the activity of anti-Paracoccidioides of Piper regnellii and
“Baccharis dracunulifolia”3 0 m g / L[ 17, 19]. The results
expressed in this study were excellent for P. brasiliensis,M I C
of 0.12mg/L for both molecules at a concentration 65 times
lower than the results of the studies mentioned above.
The systemic mycosis caused by yeasts Cryptococcus spp.
has increased because of AIDS [20]. In the current results
indicate that the molecules had an excellent MIC for the
yeaststhisgenus,rangingfrom0.48to3.9mg/Lformaytenin
and 0.97 to 7.8 for pristimerin. Another study revealed the
antifungal activity of extracts of Maytenus undata against C.
neoformans, which showed MIC of 0.09mg/L after 24h, and
0.18mg/L after 48h [21]. The species Candida are classiﬁed
as the fourth most common pathogen in hospitals and are
associated with increased mortality of bloodstream infec-
tions due to these fungi having high resistance to existing
antifungal [22]. For this yeast, the pristimerin showed potent
activity, with the exception of C. glabrata ATCC 90030,
which showed moderate activity, and C. albicans ATCC
90028, which obtained low antifungal activity. Maytenin
showed moderate antifungal activity for this specie. For
C. albicans, maytenin and pristimerin showed fungicide
activity; however, the Candida non-albicans the result was
fungistatic, except for C. glabrata in contact pristimerin.
Although dermatophyte infections are restricted to cer-
tain areas of the epidermis, they can be invasive and
cause serious injury [23]. Due to the high incidence there
is a great need to ﬁnd new drugs which act on the
dermatophytes. Maytenin showed potent activity with MIC
ranging from 1.95 to 3.9mg/L. For ﬁlamentous fungi, the
pristimerin showed moderate activity, with the exception
of Trichophyton mentagrophytes ATCC 44131, which showed
a MIC of 62.5mg/L. Many studies have demonstrated the
plant antifungal potential against these dermatophytes [23–
25], as the study of Lau et al. 2010 [24], that evaluated
extracts Eucalypti Folium and Fructus Psoraleae Globuli.B o t h
the pure compounds eﬀectively inhibit the growth of T.
mentagrophytes and T. rubrum [25].
Invasive aspergillosis is an important cause of mortality
in transplant patients [26]. Maytenin had better results
against Aspergillus niger with an MIC value of 0.97mg/L,
whereas the MIC for A. fumigatus was 125mg/L and
pristimerin was similar for both 250mg/L. Maytenin showed
good fungicide activity for most ﬁlamentous fungi, while
pristimirin showed high MIC (Table 1).
On the other hand, the cytotoxicity tests performed with
NOK (keratinocytes oral mucosa) showed that the exper-
imental substances are not cytotoxic to this cell examined
in experiment (Table 1). Although most of the antifungal
agentsavailableonthemarketareofsyntheticorigin,natural
products of the study received the attention of researchers,
mainly, due to the occurrence of unwanted factors, such as
the resistance of some strains the conventional antifungal
agents—especially in immunocompromised individuals—
andthepresenceofthesetoxiceﬀects.Figueiredoetal.(1998)Evidence-Based Complementary and Alternative Medicine 5
found antimalarial activity of various substances, including
the pristimerin but the cytotoxicity was only for the 17-
(methoxycarbonyl)-28-nor-isoiguesterin in adenocarcinoma
cell line HT-29 [27].
With respect to selectivity index (SI), it is known that
the higher the SI of a substance, the greater is its security.
In our study we found that the maytenin substance had SI
above 1.0 for all species tested, so we can demonstrate the
safe use of this. Likewise, the pristimerin presented high SI
against some fungal species, as described for H. capsulatum
(SI 13.40). However, when comparing the two substances,
maytenin still showed better results (Table 1).
5. Conclusion
The results of this study indicate the potential use of
maytenin and pristimerin for the treatment of fungal
infections, which showed a potent antifungal activity against
the fungi studied. Therefore, the data obtained are promis-
ing. Although the medicinal plant “Maytenus ilicifolia”i s
consolidated in the treatment of gastritis and ulcers more
pharmacological studies will be necessary to evaluate these
m o l e c u l e sa sa n t i f u n g a lp r o t o t y p e s .
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